TY - JOUR
T1 - Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent
AU - Mbeutcha, Aurélie
AU - Lucca, Ilaria
AU - Margulis, Vitaly
AU - Karam, Jose A.
AU - Wood, Christopher G.
AU - de Martino, Michela
AU - Mathieu, Romain
AU - Haitel, Andrea
AU - Xylinas, Evanguelos
AU - Kluth, Luis
AU - Rouprêt, Morgan
AU - Karakiewicz, Pierre I.
AU - Briganti, Alberto
AU - Rink, Michael
AU - Rieken, Malte
AU - Weizer, Alon Z.
AU - Raman, Jay D.
AU - Rioux-Leclecq, Nathalie
AU - Bolenz, Christian
AU - Bensalah, Karim
AU - Lotan, Yair
AU - Seitz, Christian
AU - Remzi, Mesut
AU - Shariat, Shahrokh F.
AU - Klatte, Tobias
N1 - Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Background: Excision repair cross-complementing 1 (ERCC1) has been associated with outcomes of urothelial carcinoma of the bladder, but was not yet studied in upper tract urothelial carcinoma (UTUC). The aim of this study was to assess the prognostic role of ERCC1 expression in a large international cohort of UTUC patients. Methods: Immunohistochemical ERCC1 expression was evaluated in 716 UTUC patients who underwent radical nephroureterectomy with curative intent. ERCC1 was considered positive when the H-score was >1.0. Associations with overall survival and cancer-specific survival were assessed using univariable and multivariable Cox models. Results: ERCC1 was expressed in 303 tumors (42.3 %) and linked with the presence of tumor necrosis (16.2 vs. 10.4 %, p = 0.023), but not with any other clinical or pathological variable. ERCC1 status did not predict cancer-specific survival and overall survival on both univariable (p = 0.70 and 0.32, respectively) and multivariable analyses (p = 0.48 and 0.33, respectively). Conclusions: ERCC1 is expressed in a significant proportion of UTUC and is linked with tumor necrosis, but its expression appears not to be associated with prognosis following radical nephroureterectomy.
AB - Background: Excision repair cross-complementing 1 (ERCC1) has been associated with outcomes of urothelial carcinoma of the bladder, but was not yet studied in upper tract urothelial carcinoma (UTUC). The aim of this study was to assess the prognostic role of ERCC1 expression in a large international cohort of UTUC patients. Methods: Immunohistochemical ERCC1 expression was evaluated in 716 UTUC patients who underwent radical nephroureterectomy with curative intent. ERCC1 was considered positive when the H-score was >1.0. Associations with overall survival and cancer-specific survival were assessed using univariable and multivariable Cox models. Results: ERCC1 was expressed in 303 tumors (42.3 %) and linked with the presence of tumor necrosis (16.2 vs. 10.4 %, p = 0.023), but not with any other clinical or pathological variable. ERCC1 status did not predict cancer-specific survival and overall survival on both univariable (p = 0.70 and 0.32, respectively) and multivariable analyses (p = 0.48 and 0.33, respectively). Conclusions: ERCC1 is expressed in a significant proportion of UTUC and is linked with tumor necrosis, but its expression appears not to be associated with prognosis following radical nephroureterectomy.
UR - http://www.scopus.com/inward/record.url?scp=84949638644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949638644&partnerID=8YFLogxK
U2 - 10.1007/s00345-015-1737-7
DO - 10.1007/s00345-015-1737-7
M3 - Article
C2 - 26658888
AN - SCOPUS:84949638644
SN - 0724-4983
VL - 34
SP - 1155
EP - 1161
JO - World Journal of Urology
JF - World Journal of Urology
IS - 8
ER -